Blomme S, Smets L, Van Ranst M, Boeckx N, Van Laer C
Clinical Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Acta Clin Belg. 2022 Apr;77(2):241-246. doi: 10.1080/17843286.2020.1814649. Epub 2020 Sep 4.
Coronavirus disease 2019 (COVID-19) was first discovered in Wuhan, China, in December 2019, and soon spread around the entire world. As no effective treatment is known, prediction of disease severity is very important in order to estimate a patients outcome. Aim of this study was to evaluate routine hematology parameters in time after admission.
Data from routine blood analyses from confirmed COVID-19 cases admitted to the University Hospital of Leuven in Belgium were collected. COVID-19 patients (n = 197) were assigned to three groups: a 'non-ICU' group, a 'ICU' group and a 'deceased' group. A control group of 60 Influenza A (non-COVID-19) patients was also included. The parameters evaluated were platelet count (PLT, 10/L), hemoglobin concentration (Hb, g/dL), leukocyte count (LEU, 10/L), neutrophil count (NEU, %), eosinophil count (EO, %), lymphocyte count (LYM, %) and monocyte count (MONO, %).
Deceased COVID-19 patients had significant lower platelet count, higher leukocyte/neutrophil count, and lower eosinophil/lymphocyte/monocyte count compared to recovered patients. Especially lymphocyte count showed important differences; they were significantly lower between day 9 and 12 after admission making this time window important in predicting clinical worsening of a patient.
Patients with COVID-19 with poor outcome showed significant differences in results of routine hematological parameters compared with patients that recovered. Especially lymphocyte count can be helpful in the prediction of a patients outcome.
2019年冠状病毒病(COVID-19)于2019年12月在中国武汉首次发现,并迅速蔓延至全球。由于尚无有效的治疗方法,预测疾病严重程度对于评估患者预后非常重要。本研究的目的是评估入院后及时的常规血液学参数。
收集了比利时鲁汶大学医院确诊的COVID-19病例的常规血液分析数据。COVID-19患者(n = 197)被分为三组:“非重症监护病房”组、“重症监护病房”组和“死亡”组。还纳入了60例甲型流感(非COVID-19)患者作为对照组。评估的参数包括血小板计数(PLT,10⁹/L)、血红蛋白浓度(Hb,g/dL)、白细胞计数(LEU,10⁹/L)、中性粒细胞计数(NEU,%)、嗜酸性粒细胞计数(EO,%)、淋巴细胞计数(LYM,%)和单核细胞计数(MONO,%)。
与康复患者相比,死亡的COVID-19患者血小板计数显著降低,白细胞/中性粒细胞计数升高,嗜酸性粒细胞/淋巴细胞/单核细胞计数降低。尤其是淋巴细胞计数显示出重要差异;入院后第9天至12天之间显著降低,这使得该时间窗对于预测患者临床病情恶化很重要。
与康复患者相比,预后不良的COVID-19患者在常规血液学参数结果上存在显著差异。尤其是淋巴细胞计数有助于预测患者预后。